PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Ridgeback Biotherapeutics, 3480 Main Highway, Unit 402, Miami, FL, 33133, USA.\', \'Emory University School of Medicine, Drug Innovations at Emory (DRIVE) and Emory Institute of Drug Development (EIDD), 954 Gatewood Road, Atlanta, GA, 30329, USA.\', \'Covance Clinical Research Unit Ltd., Springfield House, Hyde Street, Leeds, LS2 9LH, UK.\', \'Covance, Inc., 6 Drive, Research Triangle Park, Moore, NC, 27709, USA. oren.cohen@covance.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1186/s13063-021-05538-5
?:doi
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 34425873
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
is ?:relation_isRelatedTo_publication of
?:title
  • Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34425873>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34425873>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all